- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Pixantrone lands orphan drug status in Europe
The European Medicines Agency has granted orphan drug status to Cell Therapeutics' pixantrone for the treatment of diffuse large B-cell lymphoma (DLBCL), allowing the company to move ahead with a Marketing Authorization Application (MAA) by the middle of the year.
In the US, Cell Therapeutics has submitted a New Drug Application (NDA) to the FDA for pixantrone to treat relapsed/refractory aggressive Non-Hodgkin's lymphoma (NHL), which will be reviewed by the FDA's Oncologic Drugs Advisory Committee (ODAC) in February 2010. Currently fast-tracked, pixantrone's FDA status will be determined in late April 2010.